<DOC>
	<DOCNO>NCT00543972</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate dose AVE9633 characterize dose limit toxicity ( y ) . Secondary objective determine anti-leukemia activity , global safety PK profile .</brief_summary>
	<brief_title>Dose Escalation Safety Pharmacokinetic Study AVE9633 Single Agent Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients CD33positive acute myeloid leukemia , refractory relapsed standard treatment curative option available ECOG performance status 0 2 Therapy gemtuzumab ozogamicin ( Mylotarg ) within 6 month prior inclusion Allogenic transplantation within 6 month prior inclusion Prior therapy ( chemotherapy , target agent , radiotherapy ) within 3 week except hydroxyurea leukophoresis Previous treatment AVE9633 Poor kidney , liver bone marrow function Any serious active disease comorbid condition , opinion principle investigator , interfere safety compliance study Pregnant breastfeed woman Patient reproductive potential without effective birth control methods The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>